Abstract: A composition may be used in treating or preventing a virus infection in a subject, wherein the virus is from the Paramyxoviridae family and wherein the composition includes an extract of black currants and bilberries. The composition may contain an extract from black currants and bilberries in a weight ratio in a range of from 0.5:1 to 1:0.5. The extract may be an alcoholic extract, such as a methanol extract. The composition may be administered to the subject 1 to 10 oral dosages of at least 80 mg anthocyanins each per day, preferably 3 to 6 oral dosages of at least 80 mg anthocyanins each per day. The subject may not have received a measles vaccination or have previously been exposed to the measles virus.

Abstract: Compositions may be used in treating or preventing a virus infection in a subject, wherein the virus is from the Coronaviridae family and wherein the composition includes an extract of black currants and/or bilberries. The black currants may be the fruit of Ribes nigrum, and/or the bilberries may be the fruit of Vaccinium myrtillus. The extract may be of the pomaces of the black currants and/or the bilberries.

Abstract: A composition may be used in treating or preventing a virus infection in a subject, wherein the virus is from the Paramyxoviridae family and wherein the composition includes an extract of black currants and bilberries. The composition may contain an extract from black currants and bilberries in a weight ratio in a range of from 0.5:1 to 1:0.5. The extract may be an alcoholic extract, such as a methanol extract. The composition may be administered to the subject 1 to 10 oral dosages of at least 80 mg anthocyanins each per day, preferably 3 to 6 oral dosages of at least 80 mg anthocyanins each per day. The subject may not have received a measles vaccination or have previously been exposed to the measles virus.

Abstract: The present invention is related to composition for use in treating or preventing a cancer in a subject, wherein the cancer comprises cancer cells that are CD4+, and wherein the composition comprises one or more of an extract of black currants, an extract of bilberries, and an anthocyanin.

Abstract: A composition may be used in treating or preventing a virus infection in a subject, wherein the virus is from the Herpesviridae family and wherein the composition includes an extract of black currants and bilberries. The composition may contain an extract from black currants and bilberries in a weight ratio of 0.5:1 to 1:0.

Abstract: Combined preparations including an anthocyanin composition and an antiviral agent for use in treating or preventing a virus infection in a subject, wherein the anthocyanin composition includes an extract of black currants, an extract of bilberries, an extract of red grapes, and/or delphinidin 3 glucoside, wherein the virus is from the Herpesviridae family and the antiviral agent is a Herpesviridae antiviral agent, and wherein the anthocyanin composition and the antiviral agent are for simultaneous, separate or sequential use.

Abstract: The present invention is related to Delphinidin-3-glucoside (D3G) for use in treating or preventing a vims infection in a subject, wherein the virus is from the Herpesviridae family.

Abstract: The present invention provides novel HIV protease inhibitors containing substituted borane, carborane or metallacarborane clusters with 6 to 12 boron atoms in each cluster. The charge of each borane, carborane or metallacarborane cluster is 0, ?1 or ?2. The number of borane, carborane or metallacarborane clusters in the inhibitor molecule is 1 to 9, and the carborane clusters in metallacarborane inhibitors are coordinated to transition metal atom, selected from the group containing cobalt, iron, nickel and ruthenium. In the cluster, heteroatoms can be present, such as nitrogen, phosphorus, silicon, germanium, tin and sulphur. The present invention covers pharmaceutical compositions containing these inhibitors and their use, both in vitro and in vivo. They are characterized by high effectiveness and stability.

Abstract: The present invention provides novel HIV protease inhibitors containing substituted borane, carborane or metallacarborane clusters with 6 to 12 boron atoms in each cluster. The charge of each borane, carborane or metallacarborane cluster is 0, ?1 or ?2. The number of borane, carborane or metallacarborane clusters in the inhibitor molecule is 1 to 9, and the carborane clusters in metallacarborane inhibitors are coordinated to transition metal atom, selected from the group containing cobalt, iron, nickel and ruthenium. In the cluster, heteroatoms can be present, such as nitrogen, phosphorus, silicon, germanium, tin and sulphur. The present invention covers pharmaceutical compositions containing these inhibitors and their use, both in vitro and in vivo. They are characterized by high effectiveness and stability.